AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Novonesis AS

Director's Dealing Jan 3, 2025

3377_rpt_2025-01-03_cfeb2b1d-345e-4c5f-aef8-23728bebcb6b.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program.

1. Details ofthe person discharging managerial responsibilities/person closely associated
a) Name Henrik Jørck Nielsen
2. Reason for the notification
a) Position/status Executive Vice President, Strategy & Integration
) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Novozymes A/S, part of Novonesis Group
b) LEI 529900T6WNZXD2R3JW38
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description ofthe financial
instrument, type of instrument
B-shares
Identification code DK0060336014
b) Nature of the transaction Shares received as part of legacy Chr. Hansen incentive
program
c) Price(s) and volume(s) Volume
Price (DKK)
Aggregated information 13,878 shares
411.90
d) -
Aggregated volume
-
Price
13,878 shares
5,716,348.20 DKK
e) Date of the transaction January 2, 2025
f) Place of the transaction Outside a trading venue

January 3, 2025 Company announcement No. 1

Contact information

Tobias Bjorklund +45 3077 8682 [email protected]

Anders Enevoldsen +45 5350 1453 [email protected]

Katrine Spedtsberg Poulsen [email protected]

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark

CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38

Talk to a Data Expert

Have a question? We'll get back to you promptly.